ALSO NOTED: Pharmaxis reports Phase II CF data; New Zealand publishes biotech industry stats; and much more...

> Pharmaxis announced today that a Phase II clinical trial in children with cystic fibrosis demonstrated excellent lung function improvement following three months treatment with Bronchitol that matched that achieved by the current marketed product, Genentech's rhDNase. Release

> New Zealand has release new statistics on the country's biotech industry. Release

> Malaysian officials say the country is on track to become a biotech hub by 2020. Report

> The FDA has allowed Eisai to resume a Phase I clinical trial of E2012, an Alzheimer's treatment. Release

> Big Pharma looks more and more like a big ostrich these days, Forbes suggests. The brouhaha over Vytorin and Zetia this week is a case in point. Report

Most popular this week: Lilly readies Phase III Alzheimer's trial. Report

And Finally... Researchers are pushing ahead with the first human trials of an ebola vaccine. Report

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.